---
title: "AstraZeneca announces BRL 0.87 dividend per unit, payable Sept. 14"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/298614475.md"
description: "AstraZeneca declared a cash dividend of R$ 0.87 per unit for the second half of 2026. Shares trade with entitlement through August 5, 2026, and the payment date is set for September 14, 2026."
datetime: "2026-09-10T14:53:14.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/298614475.md)
  - [en](https://longbridge.com/en/news/298614475.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/298614475.md)
generator: "portal-rs"
---

# AstraZeneca announces BRL 0.87 dividend per unit, payable Sept. 14

-   AstraZeneca declared a cash dividend of R$ 0.87 per unit for 2H 2026. \* Shares trade with entitlement through Aug. 5, 2026. \* Payment date set for Sept. 14, 2026. Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. AstraZeneca plc published the original content used to generate this news brief on September 10, 2026, and is solely responsible for the information contained therein. © Copyright 2026 - Public Technologies (PUBT) Original Document: here

### Related Stocks

- [AZN.US](https://longbridge.com/en/quote/AZN.US.md)
- [AZN.UK](https://longbridge.com/en/quote/AZN.UK.md)

## Related News & Research

- [AstraZeneca Q3 2026 reported EPS rises 23% to $2.02](https://longbridge.com/en/news/303734456.md)
- [5-AstraZeneca CEO strikes bullish tone on pipeline as stock rallies](https://longbridge.com/en/news/303770251.md)
- [AZN: Four oncology programmes delivered pivotal results, supporting a broad pipeline and $80bn 2030 ambition](https://longbridge.com/en/news/303125613.md)
- [Amgen, AstraZeneca Drug Combo Shows Promising Survival Results in Tough-To-Treat Lung Cancer](https://longbridge.com/en/news/303091953.md)
- [AstraZeneca’s Imfinzi-tarlatamab combination cuts death risk 58% in Phase III lung cancer trial](https://longbridge.com/en/news/302966828.md)

---
> **Disclaimer: This article is for reference only and does not constitute any investment advice.**